VivoSeq
Oncology

Cancer

6

Pipeline Programs

53

Active Trials

37

Companies Involved

Cancer is an early-stage landscape with 6 programs across 37 companies. The most active players are Novartis, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Pfizer.

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

36/100

Mech. Concentration

25/100

Completion Rate

79/100

Attrition Rate

14/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

83%

Small molecule

5 of 6 classified programs — the dominant modality here.

17%ALL OTHERSCell therapy117%

Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 78% of 9 pipeline programs.

Trial Status

226

clinical trials

Completed120 · 53%
Recruiting32 · 14%
Terminated22 · 10%
Unknown status18 · 8%
Active, not recruiting17 · 8%
Withdrawn10 · 4%
Other7 · 3%

Trial Activity

226 trials

Evaluation Using FAPI-PET Targeting Cancer-associated Fibroblasts
Recruiting··N/A·NCT05442151·200 enrolled
The MASTER Study (MAmmary Cancer STatin ER Positive Study)
Recruiting··Phase 3·NCT04601116·3,360 enrolled
CIRculating CANcer MAster-Protocol
Recruiting·HHospices Civils de Lyon·N/A·NCT05089747·6,000 enrolled
Page 1 of 16

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)